Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 16.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 387,282 shares of the company’s stock after purchasing an additional 53,301 shares during the period. Robeco Institutional Asset Management B.V. owned 0.38% of Neurocrine Biosciences worth $44,623,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. RFP Financial Group LLC increased its position in Neurocrine Biosciences by 346.5% in the first quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after buying an additional 149 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter worth about $28,000. Innealta Capital LLC bought a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $30,000. New Covenant Trust Company N.A. bought a new stake in Neurocrine Biosciences in the 1st quarter valued at about $32,000. Finally, EdgeRock Capital LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter valued at about $35,000. 92.59% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on NBIX. Piper Sandler raised Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $131.00 to $159.00 in a report on Thursday, August 29th. JPMorgan Chase & Co. boosted their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Citigroup increased their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a “neutral” rating in a research note on Friday, August 2nd. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Raymond James reiterated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $163.91.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Gary A. Lyons sold 11,570 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $150.43, for a total value of $1,740,475.10. Following the transaction, the director now directly owns 119,047 shares of the company’s stock, valued at approximately $17,908,240.21. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the sale, the director now directly owns 37,491 shares in the company, valued at $5,499,554.79. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gary A. Lyons sold 11,570 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $150.43, for a total transaction of $1,740,475.10. Following the transaction, the director now owns 119,047 shares in the company, valued at approximately $17,908,240.21. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,063 shares of company stock valued at $7,023,330 in the last quarter. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Performance

NBIX stock opened at $121.53 on Wednesday. The firm has a 50 day simple moving average of $118.51 and a 200 day simple moving average of $133.33. Neurocrine Biosciences, Inc. has a 52 week low of $103.63 and a 52 week high of $157.98. The stock has a market cap of $12.30 billion, a P/E ratio of 32.58 and a beta of 0.35.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.